The Alliance for Regenerative Medicine Applauds CMS's Decision to Establish New DRG for CAR-T Therapies

WASHINGTON, DC – May 11, 2020

The Alliance for Regenerative Medicine (ARM) applauds the Centers for Medicare and Medicaid Services’ (CMS) decision to include a provision creating a new diagnosis-related group (DRG) for CAR-T therapies in their FY21 IPPS rule.

The creation of a new DRG is an important step to ensuring that Medicare providers are appropriately and sustainably reimbursed for administering CAR-T therapies. CMS has signaled that they are committed to providing patient access to these innovative therapies. CAR-T therapies provide an unprecedented therapeutic benefit to patients with severe blood cancers. Under the current reimbursement system, providers can lose more than $100,000 when administering CAR-T to Medicare patients.


About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit